Let’s be honest about cardiovascular risk after the first heart attack or stroke
LET’S BE HONEST about cardiovascular risk after the first heart attack or stroke
After a heart attack, the recurrence rate of another cardiovascular event or heart procedure is up to
50%within a year.1
EVERY YEAR, MORE THAN
PEOPLE IN THE UNITED STATES SUFFER A HEART ATTACK OR STROKE.2
For many people, the risk of being
impaired by a stroke
is feared more than death from heart disease, including heart attack.3,4
Are we doing enough TO PROTECT OUR HEARTS, ESPECIALLY AFTER A HEART ATTACK OR STROKE?
Americans have high cholesterol and oftentimes, many are solely focused on controlling it, even though the risk of heart attack or stroke remains.5,6
Cardiovascular disease is the number one killer of women and men, and after a first heart attack, around 20% of patients age 45 and older will have another heart attack within 5 years.7-10
is how much statins reduce your odds of a life-threatening CV event. Statins are the first step—but they don’t fully protect you from a serious heart attack or stroke. There's more you can do.6
It's clear that cardiovascular disease, including heart attack or stroke, is too risky to ignore.
Millions of patients at risk of heart attack or stroke may be unknowingly receiving medications that have not shown to reduce CV risk on top of statins.11,12
Talk to your doctor today about switching to FDA-approved therapies, as you may still be at risk of having a heart attack or stroke.12,13
AFTER A FIRST HEART ATTACK OR STROKE, THERE'S MORE YOU CAN DO TO LOWER THE RISK OF ANOTHER1
References: 1. Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201(suppl 1):S1-S7. 2. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation. 2022;145:e153-e639. 3. Samsa GP, Matchar DB, Goldstein L, et al. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J. 1998;136(4 Pt 1):703-713. 4. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke. 1994;25(9):1721-1725. 5. Virani SS, Alonso A, Aparicio HJ, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2021 Heart disease and stroke statistics update fact sheet at-a-glance. https://www.heart.org/-/media/phd-files-2/science-news/2/2021-heart-and-stroke-stat-update/2021_heart_disease_and_
stroke_statistics_update_fact_sheet_at_a_glance.pdf. Accessed March 8, 2022. 6. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343. 7. Centers for Disease Control and Prevention. Women and heart disease. https://www.cdc.gov/heartdisease/women.htm. Accessed March 8, 2022. 8. Centers for Disease Control and Prevention. Heart disease facts. https://www.cdc.gov/heartdisease/facts.htm. Accessed March 8, 2022. 9. National Institutes of Health. Coronary heart disease. https://www.nhlbi.nih.gov/health-topics/coronary-heart-disease. Accessed March 8, 2022. 10. American Heart Association. Life after a heart attack. https://www.heart.org/en/health-topics/heart-attack/life-after-a-heart-attack. Accessed March 8, 2022. 11. What you need to know about dietary supplements. US Food and Drug Administration website. https://www.fda.gov/food/dietarysupplements/usingdietarysupplements/ucm109760.htm. Updated November 2017. Accessed March 8, 2022. 12. Department of Health and Human Services. [Docket no. FDA–2016–N–1127]: AbbVie Inc., et al; Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Federal Register. 2016;81(74):22612-22613. 13. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.